Ipatasertib in combination with abiraterone and prednisone for metastatic castrate resistant prostate cancer – first line
Ipatasertib in addition to abiraterone and prednisone is in clinical development for the first line treatment of metastatic castrate resistant prostate cancer (mCRPC). Prostate cancer is a cancer of the prostate gland and mCRPC is when the cancer has spread to parts of the body other than the prostate, and it is able to grow and spread even though drugs or other treatments to lower the amount of male sex hormones are being used to manage the cancer. The symptoms of prostate cancer may vary depending on the stage but can include pain, tiredness, and problems emptying the bladder and the bowels. Treatment options for mCRPC are currently limited.
Ipatasertib is an oral, highly specific medicine designed to target and bind to all three forms of protein called AKT. By binding to AKT, ipatasertib blocks the PI3K/AKT signalling pathway and may prevent cancer cell growth and survival. If licensed, ipatasertib in addition to abiraterone and prednisone will provide a new regimen for mCRPC.